methanesulfonate;trimethyl-[(4E,8E,12E,16E)-4,8,12,17-tetramethyl-20-(trimethylazaniumyl)icosa-4,8,12,16-tetraenyl]azanium

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: methanesulfonate;trimethyl-[(4E,8E,12E,16E)-4,8,12,17-tetramethyl-20-(trimethylazaniumyl)icosa-4,8,12,16-tetraenyl]azanium
• 化学式: C32H64N2O6S2
• 分子量: 637.0
• InChiKey: WJQQUPNVHIJWBW-WUQBIVCFSA-L

计算性质

• 辛醇/水分配系数(LogP)：
  6.41
• 重原子数：
  42
• 可旋转键数：
  17
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  131
• 氢给体数：
  0
• 氢受体数：
  6

文献信息

• Nanoparticles based on bioconjugate of GAG
  申请人：Centre National de la Recherche Scientifique

  公开号：EP2742955A1

  公开（公告）日：2014-06-18

  The present invention relates to nanoparticles comprising at least one negatively charged glycosaminoglycan-type macromolecule or a derivative thereof, non-covalently coupled to at least one molecule of a cationic hydrocarbon-based radical of squalene nature represented by the formula (I) which follows: wherein: A, B, C, D, E and F are a hydrogen atom or a methyl group; Z and Y represent a radical an ethyltrialkylammonium radical, an ethylguanidium radical or a 1-[ethylideneamino]guanidinium radical with the proviso that at least one of Z and Y is different from the symbol * showing the position of the attachment of the radical to the structure; and n is equal to 1 or 2. The present invention also relates to a method for preparing said nanoparticles, and to a lyophilisate, a solid dosage form and pharmaceutical or dermatological compositions comprising said nanoparticles. Said nanoparticles are useful as medicines and more particularly as anticoagulant agents.

  本发明涉及含有至少一种带负电荷的糖氨基聚糖类大分子或其衍生物的纳米颗粒，非共价结合至至少一种具有化学式(I)所示的鲨烯性质的阳离子烃基自由基分子，其中： 其中： A、B、C、D、E和F为氢原子或甲基基团；Z和Y代表一个基团，即乙基三烷基铵基团、乙基胍基团或1-[乙基亚氨基]胍基团，但至少其中一个是与*符号不同的附加基团的位置；n等于1或2。 本发明还涉及一种制备上述纳米颗粒的方法，以及含有该纳米颗粒的冻干物、固体剂量形式和药用或皮肤科学组合物。该纳米颗粒可用作药物，特别是作为抗凝剂。